NEUROMYELITIS OPTICA SPECTRUM DISORDER

This study tests a drug called satralizumab in children aged 2 to 11 who have a rare autoimmune disease called NMOSD. The main goal is to see how the drug moves through the body and if it can safely reduce relapses. Only 8 children will take part, and the results will help doctor…

This early-stage study tests a new cell therapy called CNCT19 in 18 adults with relapsed or treatment-resistant autoimmune neurological diseases like neuromyelitis optica. The goal is to see if it is safe and can help control the disease by targeting certain immune cells. Partici…

This pilot study tests the drug ofatumumab in 5 people with a rare autoimmune disease called NMOSD. Participants receive injections over 48 weeks. The main goal is to see if the drug reduces the number of relapses compared to before treatment. It is an early, small study focused …

This study tests a drug called inebilizumab in 15 children aged 2 to 17 with neuromyelitis optica spectrum disorder (NMOSD), a rare condition where the immune system attacks the optic nerves and spinal cord. The drug aims to reduce relapses by targeting certain immune cells. Rese…

This early-phase study tests a 4-week training program that uses mixed reality to guide precise movements, like stacking virtual objects. The goal is to see if this can improve walking speed, balance, and thinking in people with multiple sclerosis. Thirty adults with MS will part…

This study is a long-term registry for adults with AQP4+ neuromyelitis optica spectrum disorder (NMOSD) who are already taking Alexion C5 inhibitor drugs like eculizumab or ravulizumab. It will collect information on relapses, safety, and quality of life over many years to unders…

This study looks at whether a 10-minute video about palliative care can help people with multiple sclerosis (MS) understand their options and make decisions that match their values. Half of the 50 participants will watch the video, and the other half will read a standard informat…

This study follows 60 women with neuromyelitis optica spectrum disorder (NMOSD) who received UPLIZNA during pregnancy or within 6 months before conception. Researchers will collect data on pregnancy outcomes, including birth defects, preterm birth, and infant development over 10 …

This registry follows 1,500 women with multiple sclerosis (MS) or related conditions through pregnancy and after childbirth. Researchers will track relapses, use of disease-modifying drugs, and outcomes for both mothers and children. The goal is to better understand how MS and it…